166 related articles for article (PubMed ID: 22549243)
1. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.
Yang L; You S; Kumar V; Zhang C; Cao Y
J Exp Clin Cancer Res; 2012 May; 31(1):40. PubMed ID: 22549243
[TBL] [Abstract][Full Text] [Related]
2. Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.
Huang S; Guo Y; Jacobi A; Li Z; Huang S; He J; Liu X; Tang Y
Cell Physiol Biochem; 2016; 39(2):709-20. PubMed ID: 27448695
[TBL] [Abstract][Full Text] [Related]
3. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis.
Fu Z; Smith PC; Zhang L; Rubin MA; Dunn RL; Yao Z; Keller ET
J Natl Cancer Inst; 2003 Jun; 95(12):878-89. PubMed ID: 12813171
[TBL] [Abstract][Full Text] [Related]
4. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
5. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells.
Krupski T; Harding MA; Herce ME; Gulding KM; Stoler MH; Theodorescu D
Growth Factors; 2001; 18(4):287-302. PubMed ID: 11519827
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
[TBL] [Abstract][Full Text] [Related]
7. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP
Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
[TBL] [Abstract][Full Text] [Related]
10. Cellular interactions in the tropism of prostate cancer to bone.
Sikes RA; Nicholson BE; Koeneman KS; Edlund NM; Bissonette EA; Bradley MJ; Thalmann GN; Cecchini MG; Pienta KJ; Chung LW
Int J Cancer; 2004 Jul; 110(4):497-503. PubMed ID: 15122581
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication.
Hoshino Y; Hayashida T; Hirata A; Takahashi H; Chiba N; Ohmura M; Wakui M; Jinno H; Hasegawa H; Maheswaran S; Suematsu M; Kitagawa Y
Mol Cancer; 2014 May; 13():102. PubMed ID: 24885802
[TBL] [Abstract][Full Text] [Related]
12. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.
Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET
Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351
[TBL] [Abstract][Full Text] [Related]
13. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
Huang S; He P; Peng X; Li J; Xu D; Tang Y
Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
[TBL] [Abstract][Full Text] [Related]
14. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
15. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
17. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
18. Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells.
Moon DO; Choi YH; Moon SK; Kim WJ; Kim GY
Toxicol In Vitro; 2010 Oct; 24(7):1927-34. PubMed ID: 20696233
[TBL] [Abstract][Full Text] [Related]
19. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells.
Muir C; Chung LW; Carson DD; Farach-Carson MC
Clin Exp Metastasis; 2006; 23(1):75-86. PubMed ID: 16826426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
